And there are a number of potentials:
Othepedics
Intravenous
MSC (Crohns/GVHD)
Japan (excluding JCR)
According to MSB website , we currently have 2 partnered (Teva ;JCR)
The comment by Jason below re a potential 3rd partnering for a P2 application is interesting as I always envisaged the 3rd deal to be P3 Orthopedics (spinal fusion).
If anyone has access to Jason's note - it would be interesting to understand what P2 application he is referring to ?
Good luck all.
Jason Zhang, Edison Investment Research (5/27/14) "Mesoblast Ltd. intends to initiate a Phase 3 trial of mesenchymal precursor cells in discogenic low back pain later this year, following the successful Phase 2 trial that reported in February. . .now a leading contender in the field, Mesoblast could have five active programs in Phase 3 (two partnered) and four in Phase 2 studies (one partnered) with nine clinical candidates by the end of this year. We expect CEP-41750 to become the leading stem cell therapy for congestive heart failure."
MSB Price at posting:
$4.27 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)